Avid Bioservices Inc. / Peregrine Pharmaceuticals Inc. / Stephen T. Worsley / M.P.H. / D. / /
Country
United States / /
Currency
USD / / /
Event
FDA Phase / /
Facility
Advancing Clinical Pipeline / /
IndustryTerm
contract manufacturing revenues / in-house cGMP manufacturing capabilities / biopharmaceutical / cancer therapy / Cancer therapies / clinical products / contract manufacturing revenue / Treatment for Brain Cancer / development and biomanufacturing services / in-house biomanufacturing subsidiary / /
MedicalCondition
tumor / second-line non-small cell lung cancer / cancer / tumors / NSCLC / additional disease / inflammatory cytokines / recurrent glioblastoma multiforme / non-small cell lung cancer / novel brain cancer / monoclonal antibody brain cancer / /
MedicalTreatment
brain cancer therapy / Cancer therapies / chemotherapy / immunotherapy / /
Organization
U.S. Food and Drug Administration / American Association for Cancer Research / U.S. Securities and Exchange Commission / /
Person
Robert L. Garnick / Jeff T. Hutchins / Fussey / Joseph S. Shan / Mark R. Ziebell / Kerstin B. Menander / Paul J. Lytle / Mary J. Boyd / / /
Position
Chief Financial Officer / King / Head of Regulatory Affairs / President and CEO / Vice President / Business Development / Vice President / Preclinical Development About Bavituximab / Vice President / Clinical & Regulatory Affairs Mark R. Ziebell / Esq / Vice President / Intellectual Property / Head of Business Development For Asia / Private / Vice President / General Counsel / Head / CEO / Director / Vice President / Clinical & Regulatory Affairs / /
Product
Cotara / Second-Line Non / /
ProvinceOrState
California / /
PublishedMedium
Cancer Research / /
Technology
Biomanufacturing / antibodies / chemotherapy / treating cancer / /
April, 2014 Powerful science. Novel therapies. Dedicated to patients. About Peregrine Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trial